Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5286476
Max Phase: Preclinical
Molecular Formula: C55H57F3N8O5S2
Molecular Weight: 1031.24
Associated Items:
ID: ALA5286476
Max Phase: Preclinical
Molecular Formula: C55H57F3N8O5S2
Molecular Weight: 1031.24
Associated Items:
Canonical SMILES: Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)CCCCCCc2ccc(C#Cc3ccc(N4C(=S)N(c5ccc(C#N)c(C(F)(F)F)c5)C(=O)C4(C)C)cc3)cn2)C(C)(C)C)cc1
Standard InChI: InChI=1S/C55H57F3N8O5S2/c1-34-47(73-33-62-34)38-20-15-37(16-21-38)31-61-49(69)45-28-43(67)32-64(45)50(70)48(53(2,3)4)63-46(68)12-10-8-7-9-11-40-23-17-36(30-60-40)14-13-35-18-24-41(25-19-35)66-52(72)65(51(71)54(66,5)6)42-26-22-39(29-59)44(27-42)55(56,57)58/h15-27,30,33,43,45,48,67H,7-12,28,31-32H2,1-6H3,(H,61,69)(H,63,68)/t43-,45+,48-/m1/s1
Standard InChI Key: DQQBASHTDJWTOF-FHGSKKDFSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1031.24 | Molecular Weight (Monoisotopic): 1030.3845 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Han X, Wang C, Qin C, Xiang W, Fernandez-Salas E, Yang CY, Wang M, Zhao L, Xu T, Chinnaswamy K, Delproposto J, Stuckey J, Wang S.. (2019) Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer., 62 (2): [PMID:30629437] [10.1021/acs.jmedchem.8b01631] |
Source(1):